热门资讯> 正文
GT Bizerma GAAP每股收益为-2.17美元
2024-08-15 19:44
- GT Biopharma press release (NASDAQ:GTBP): Q2 GAAP EPS of -$2.17.
- Cash of approximately $9.2 million as of June 30, 2024, anticipated to be sufficient to fund operations into 2025
More on GT Biopharma
- Financial information for GT Biopharma
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。